ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD

AstraZeneca today announced that it has completed the licensing
agreement (https://www.astrazeneca.com/media-centre/press
-releases/2016/astrazeneca-enters-into-us-licensing-agreement-with-ironwood
-pharmaceuticals-for-lesinurad-26042016.html) with Ironwood Pharmaceuticals for
the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination
of lesinurad and allopurinol. Zurampic is approved in the US, in combination
with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated
with uncontrolled gout. The fixed-dose combination will be submitted for
regulatory review in the second half of 2016.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas –
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology – as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Neil Burrows UK/Global +44 7824 350541
Vanessa Rhodes UK/Global +44 7880 400690
Karen Birmingham UK/Global +44 7818 524012
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen   +44 7818 524185
Nick Stone RIA +44 7717 618834
Henry Wheeler Oncology +44 7788 354619
Craig Marks Finance +44 7881 615764
Christer Gruvris ING +44 7827 836825
US
Lindsey Trickett CVMD +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Dial / Toll-Free   +1 866 381 7277

Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and
Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal

3 June 2016

-ENDS-

Ads